- Methodology article
- Open Access
The DNA relaxation activity and covalent complex accumulation of Mycobacterium tuberculosis topoisomerase I can be assayed in Escherichia coli: application for identification of potential FRET-dye labeling sites
© Narula et al; licensee BioMed Central Ltd. 2010
Received: 3 June 2010
Accepted: 30 September 2010
Published: 30 September 2010
Mycobacterium tuberculosis topoisomerase I (MtTOP1) and Escherichia coli topoisomerase I have highly homologous transesterification domains, but the two enzymes have distinctly different C-terminal domains. To investigate the structure-function of MtTOP1 and to target its activity for development of new TB therapy, it is desirable to have a rapid genetic assay for its catalytic activity, and potential bactericidal consequence from accumulation of its covalent complex.
We show that plasmid-encoded recombinant MtTOP1 can complement the temperature sensitive topA function of E. coli strain AS17. Moreover, expression of MtTOP1-G116 S enzyme with the TOPRIM mutation that inhibits DNA religation results in SOS induction and loss of viability in E. coli. The absence of cysteine residues in the MtTOP1 enzyme makes it an attractive system for introduction of potentially informative chemical or spectroscopic probes at specific positions via cysteine mutagenesis. Such probes could be useful for development of high throughput screening (HTS) assays. We employed the AS17 complementation system to screen for sites in MtTOP1 that can tolerate cysteine substitution without loss of complementation function. These cysteine substitution mutants were confirmed to have retained the relaxation activity. One such mutant of MtTOP1 was utilized for fluorescence probe incorporation and fluorescence resonance energy transfer measurement with fluorophore-labeled oligonucleotide substrate.
The DNA relaxation and cleavage complex accumulation of M. tuberculosis topoisomerase I can be measured with genetic assays in E. coli, facilitating rapid analysis of its activities, and discovery of new TB therapy targeting this essential enzyme.
DNA topoisomerases maintain the proper topological state of DNA required for vital cellular functions to proceed. The change in DNA topology is catalyzed via concerted breaking and rejoining of DNA coupled with DNA strand passage , forming a covalent topoisomerase complex with cleaved DNA as the catalytic intermediate. The accumulation of the covalent complex accounts for the lethal effects of many topoisomerase inhibitors that are utilized as anticancer or antibacterial drugs in therapeutic applications [2–5]. These drugs target type IB and type IIA topoisomerases, classified according to their structural and mechanistic properties. Discovery of similar topoisomerase poison inhibitors for type IA topoisomerases, which include bacterial topoisomerase I enzyme, could lead to the discovery of novel antibacterial agents that can be used for treatment of multi-drug resistant bacterial pathogens. It has been demonstrated via mutants defective in DNA rejoining that accumulation of E. coli or Yersinia pestis topoisomerase I cleavage complex in E. coli leads to rapid bacterial cell death [6, 7] validating bacterial topoisomerase I as a new therapeutic target . In addition to poison inhibitors, catalytic inhibitors that act by a different mechanism could also be useful therapeutic agents for bacterial pathogens that require a functional topoisomerase I enzyme for viability or pathogenicity. It has been suggested that at least one type IA topoisomerase enzyme activity must be present in each organism for resolving topological barriers that require single-stranded DNA cleavage . Unlike E. coli, which encodes topoisomerase III as a second type IA topoisomerase, M. tuberculosis has only one type IA topoisomerase activity. Results from previous transposon mutagenesis studies strongly suggest that the topoisomerase I function is required for M. tuberculosis growth and survival during infection [10, 11]. M. tuberculosis topoisomerase I (MtTOP1) has been proposed as a target for discovery of new TB drugs  that are urgently needed due to the large number of human deaths caused by TB globally, and the increasing incidence of TB strains resistant to all available current drugs.
To study the structure-function of MtTOP1 and to monitor its activity, it would be desirable to have a rapid genetic assay for its specific function. The E. coli strain AS17  has a mutation in the chromosomal topA gene that reduces the topoisomerase I relaxation activity, with growth permissible at 30°C but non-permissive at 42°C unless complemented by recombinant relaxation activity [14, 15]. The topoisomerase I enzyme of E. coli and M. tuberculosis shares a highly homologous transesterification domain (~67,000 kDa) that is conserved among all type IA topoisomerases. It contains the active site tyrosine residue for nucleophilic attack of DNA in the formation of the covalent cleavage complex, and residues in the TOPRIM domain required for coordination of Mg2+ during catalysis . DNA cleavage site selectivity was found to involve the preference of a cytosine at the-4 position relative to the cleavage sites preferred by topoisomerase I and reverse gyrase enzymes in the type IA family of topoisomerases [17–19]. However, the transesterification domain cannot carry out relaxation of negative supercoils in the absence of the C-terminal domain . The C-terminal domains of E. coli and M. tuberculosis topoisomerase I belong to two distinct families. The C-terminal domain of E. coli topoisomerase I has multiple tetracysteine motifs for coordination of Zn(II) ions required for relaxation activity , while the C-terminal domains of topoisomerase I found in Mycobacterium smegmatis and M. tuberculosis were found not to have any Zn(II) coordinating tetracysteine motifs .
In addition to the difference between the C-terminal domain sequences of Mycobacterium and E. coli topoisomerase I, it is also unclear if MtTOP1 can be functional in E. coli due to the significant difference in codon usage between E. coli and M. tuberculosis. The structure-function study of MtTOP1 would be greatly facilitated if a rapid genetic assay system utilizing E. coli can be established. For further study of the enzymatic properties of MtTOP1, we have initiated biochemical studies of MtTOP1 to take advantage of the absence of cysteine residue in its sequence. If a unique cysteine can be introduced into a specific position via site-directed mutagenesis without diminishing the catalytic activity, spectroscopic or chemical probes can then be introduced to study the protein-DNA interactions involved in catalysis. Spectrophotometric analysis utilizing these probes could potentially be developed into HTS assay for identification and characterization of small molecule inhibitors of MtTOP1.
In this study, we demonstrated that plasmid encoding MtTOP1 can complement E. coli AS17 with temperature sensitive topA  for growth at 42°C. In addition to demonstrating that the relaxation activity of wild-type MtTOP1 was functional in E. coli, we also showed that when a mutant version of MtTOP1, with the G116 S TOPRIM mutation that inhibits DNA religation  was overexpressed in E. coli, the SOS response is induced along with a significant decrease in viability. Therefore, the accumulation of cleavage complex formed by MtTOP1 can also be assayed in E. coli. We utilized the E. coli genetic system to identify a number of positions in MtTOP1 that could be mutated to cysteine with little or no loss of relaxation activity. The retention of relaxation activity was confirmed after the expression and purification of the mutant enzymes. One such cysteine substitution mutant enzyme MtTOP1-K524C was conjugated to a fluorescence dye for fluorescence resonance energy transfer (FRET) study with fluorescence-labeled oligonucleotide substrates.
Complementation of topA function in E. coli AS17 for growth at 42°C by M. tuberculosis topoisomerase I
Cell killing from accumulation of mutant MtTOP1 covalent complex in E. coli
The TOPRIM motif DxDxxG is strictly conserved in type IA topoisomerase sequences and plays an essential role for divalent ion coordination and cleavage-religation of DNA during catalysis [16, 22, 23]. For recombinant E. coli or Y. pestis topoisomerase I, mutation of the first aspartate residue in the TOPRIM motif to asparagine has been shown to be extremely lethal to E. coli . Substitution of the conserved glycine in the TOPRIM motif with serine in E. coli or Y. pestis topoisomerase I resulted in mutant topoisomerase I enzyme capable of DNA cleavage but defective in DNA religation . Induction of the BAD promoter regulating the expression of these Gly to Ser mutant E. coli and Y. pestis topoisomerases resulted in loss of viability of the host E. coli cells .
An attempt was made to introduce the Asn substitution at the first Asp of the TOPRIM motif found in MtTOP1 (Asp111) by site-directed mutagenesis. Clones of pMTOP with the desired D111N mutation as a single substitution could not be isolated after transformation of commonly used E. coli cloning strains even in the presence of 2% glucose to suppress transcription from the BAD promoter regardless of the recA genotype of the E. coli host cells. This was likely due to the toxic effect of the mutant MtTOP1 background expression on E. coli viability. All the isolated clones had second site mutations, similar to what was observed during attempted construction of E. coli and Y. pestis topoisomerase I mutants with the D111N mutation . This suggested that E. coli host cells can be very vulnerable to accumulation of covalent cleavage complex formed by recombinant MtTOP1 enzyme in vivo.
Plasmid pMTOP-G116S was transformed into E. coli strain JD5 and the transformants were first isolated in the presence of 2% glucose. The transformants were then replica plated onto Xgal indicator plate with 0.002% arabinose to increase the level of synthesis of mutant MtTOP1-G116 S. SOS response to the accumulated cleavage complex was evident from the blue color of the colonies in the presence of 0.002% arabinose resulting from induction of the lacZ gene under the control of the dinD1 promoter in E. coli JD5 . Treatment of an exponential phase culture of JD5/pMTOP-G116 S with 0.2% arabinose for 2 h resulted in a viable colony count ratio of ~10-4 when the number of viable colonies from induced culture were divided by the viable colony counts from the non-induced culture (Figure 2C). Induction of wild-type MtTOP1 by 0.2% arabinose reduced the viable counts of E. coli JD5 by only ~2 fold. The degree of loss of viability from the Gly to Ser mutation in pMTOP was similar to that observed previously for the same mutation in pETOP . These results showed that the accumulation of the covalent cleavage complex formed by recombinant MtTOP1 in E. coli could result in SOS induction and bacterial cell death.
Assay of relaxation activity of cysteine-substitution mutants of MtTOP1 by complementation of E. coli topA function
Effect of MtTOP1 substitutions on the complementation of topA ts function in E. coli AS17 at the non-permissive temperature
3.9 × 10-5 ± 3.3 × 10-5
0.58 ± 0.21
0.53 ± 0.24
1.1 × 10-4 ± 1.1 × 10-4
3.3 × 10-5 ± 2.0 × 10-5
2.7 × 10-4 ± 4.1 × 10-4
0.19 ± 0.15
0.097 ± 0.029
0.32 ± 0.16
0.18 ± 0.06
0.33 ± 0.17
CPM-MtTOP1-K524C relaxation activity and FRET experiments
We found that MtTOP1-H139C protein could also be labeled with fluorophores with no significant loss of relaxation activity (results not shown). However, FRET was not observed in similar studies of labeled MtTOP1-H139C with oligonucleotide substrates.
Due to the requirement of topoisomerase I function for M. tuberculosis growth and survival during infection as indicated by transposon mutagenesis studies [10, 11], discovery of specific inhibitors of MtTOP1 could lead to development of novel therapeutics urgently needed for treatment of multi-drug resistant TB. The utilization of MtTOP1 as a potential new drug target would be facilitated by development of simple assays for the catalytic function of the enzyme. It is also desirable to identify poison inhibitors that can result in accumulation of the covalent complex of MtTOP1, since such topoisomerase poison inhibitors are expected to be bactericidal, and might be useful when used in combination therapy with current TB drugs such as fluoroquinolones .
The results described here demonstrated that inhibition of DNA religation by recombinant MtTOP1 would result in killing of the E. coli host cells. Increased expression of recombinant MtTOP1 should result in hypersensitivity to its poison inhibitors. The catalytic function of recombinant MtTOP1 could also be assessed easily from its complementation of the temperature sensitive topA function in E. coli AS17 at the non-permissive temperature. Despite a potential problem from difference in codon preference of the different organisms, and divergence of the topoisomerase I C-terminal domain sequences, recombinant MtTOP1 could still form covalent cleavage complex on the E. coli chromosome and remove excess negative supercoils so that viable functions can proceed.
The E. coli cell based assays are useful in structure-function studies of the enzyme. Mutations that abolish the catalytic activity after amino acid substitutions, such as Y342A and G116 S, could be identified readily. In another approach to study the enzyme mechanism, cysteine mutagenesis sites in different regions of the enzyme which do not affect the enzyme activity could also be determined rapidly by using the E. coli AS17 complementation assay. These cysteine substitutions are designed to take advantage of the absence of cysteine in wild-type MtTOP1 sequence to introduce a sulfhydryl group that would allow conjugation of a molecular probe at a unique position on the enzyme. Cysteine mutants that could complement AS17 for growth at non-permissive temperature were found to have close to wild-type relaxation activity when purified, confirming the effectiveness of the genetic assay.
For CPM fluorophore introduced at residue K524, FRET was observed with fluorescein fluorophore placed in the single stranded region of the substrate, but not at the double stranded region. In the mechanistic model proposed for the relaxation of DNA by topoisomerase I , a single strand of DNA passes into the interior cavity of the enzyme in order to change the linking number of the DNA substrate. That would place the loop region of the single-stranded DNA in the vicinity of K524, accounting for FRET between CPM-MtTOP1-K524C and fluorescein in the single-stranded loop region of the substrate. The double-stranded region of the DNA substrate may extend from the DNA binding groove formed by subdomains I and IV , further away from the interior cavity of the enzyme and K524, explaining the absence of FRET when fluorescein was placed at the 5' or 3' end of the DNA substrate. Although H139 is closer to the active site tyrosine Y342 than K524, binding of the stem region of the DNA substrate in subdomain IV would place the DNA in opposite direction from the active site away from H139, too far for FRET to take place. We tried to attach fluorescent probes with the Y174C mutant, but the labeling efficiency was poor. Other cysteine substitution mutants will be explored in future related mechanistic studies. Cysteine substitution mutants of MtTOP1 could potentially be utilized for development of enzyme based HTS assays for inhibitors of MtTOP1 activity.
The E. coli cell based assays could also be useful for testing potential MtTOP1 inhibitors. Whole cell screenings has identified a large number of small molecules that can inhibit the growth of M. tuberculosis [30, 31], but it is often difficult to quickly determine the cellular target of antibacterial compounds without extensive follow up investigations. Previous studies showed that the topA function in E. coli AS17 can also be complemented by the type IB topoisomerase gene from Saccharomyces cerevisae . Since the type IA and type IB topoisomerases have distinctly different structures and mechanisms, an inhibitor with high specificity against type IA topoisomerase would affect growth of E. coli AS17 complemented by MtTOP1 activity at the non-permissive temperature, but should have much lower antibacterial activity against E. coli AS17 complemented by yeast topoisomerase I. This complementation assay system should facilitate the identification of lead compounds that have antibacterial activity due to interactions with M. tuberculosis topoisomerase I in their mechanism of action. Toxic compounds that reduce cell viability by interaction with cell membranes or DNA can be eliminated quickly in the pursuit of useful drug leads. To facilitate the screening, permeability of E. coli AS17 to small molecules can be enhanced by incorporation of mutations that affect the drug transporters  or membrane structure .
Rapid genetic assays in E. coli have been described here for assessing the relaxation activity and accumulation of covalent cleavage complex of recombinant MtTOP1. The genetic assay was used to identify positions in MtTOP1 that can be converted to cysteine residues without loss of function. One such cysteine was utilized as FRET-dye labeling sites to monitor interaction with DNA substrate.
PCR reaction with PfuUltra II Fusion HS DNA polymerase (from Stratagene) and genomic DNA of M. tuberculosis strain H37Rv as template was used to generate the coding sequence of MtTOP1 (gene Rv3646c). The PCR product was cloned into plasmid pBAD/thio using the TOPO cloning kit from Invitrogen to generate plasmid pBAD/thioMTOP. The 5'-PCR primer (5'AACCATGGCTGACCCGAAAACGAAGGGCCG-3') contained a recognition site for the restriction enzyme Nco I, which was used to remove the sequence coding for thioredoxin fusion tag from plasmid pBAD/thioMTOP. Following ligation and transformation of the restriction product, plasmid pMTOP which has MtTOP1 expressed under the control of the BAD promoter was obtained. Plamid pLIC-MTOP with expression of MtTOP1 under the control of the T7 promoter has been described previously . Site directed mutagenesis to introduce single amino acid substitutions were carried out with QuikChange procedures using the PfuUltra II Fusion HS DNA polymerase. Topoisomerase gene coding regions in all isolated plasmid clones were checked by DNA sequencing to confirm that no other mutations were present.
Complementation of topA function in E. coli AS17 by recombinant topoisomerase plasmid clones
E. coli AS17 (F-topA17(am) pLL1(Tet supD43,74))  transformants were grown overnight at 30°C, in Luria Bertani (LB) broth containing tetracycline (15 μg/ml) and antibiotics for selection of plasmid clones. Overnight cultures were serially diluted in sterile phosphate buffered saline and each dilution was plated on four LB agar plates with antibiotics for selection of plasmid. Two of the plates were incubated at 30°C, while the other two plates were incubated at 42°C. The viable colonies were counted after 48 hours of incubation at the respective temperatures to determine colony counts in cfu/ml. The entire study was repeated three times minimum for each plasmid clone. Complementation ratios were calculated by dividing the cfu/ml at 42°C by the cfu/ml at 30°C for each individual plasmid clone.
SOS induction and cell killing assays
Plasmid pMTOP expressing wild-type or mutant MtTOP1-G116 S proteins under the control of the BAD promoter were transformed into E. coli JD5 [JM103 dinDl ::MudI1734(KmR lacZ)] with β-galactosidase gene under the control of the SOS regulon . Transformants isolated from LB plates with 100 μg/ml ampicillin and 2% glucose were replicated onto LB plates with 35 μg/ml X-gal, 100 μg/ml ampicillin and 0.002% arabinose. SOS induction was indicated by the appearance of blue colonies after overnight incubation at 37°C as previously described for the isolation of SOS-inducing mutants of Y. pestis topoisomerase I . To measure the effect of mutant MtTOP1 expression on viability, early exponential phase culture (OD600 = 0.4) of E. coli JD5 transformants in LB medium with ampicillin (100 μg/ml) was induced with 0.2% arabinose for 2 h before serial dilution and plating on LB plates with 2% glucose and ampicillin, followed by overnight incubation at 37°C. The number of colonies (cfu/ml) obtained from the induced culture was divided by the number of colonies from the control non-induced culture to obtain the survival ratio.
Topoisomerase activity assay
MtTOP1-G116 S mutant enzyme expressed by induction of the BAD promoter with 0.2% arabinose in E. coli strain GP200, a topA deletion mutant  was purified as described previously . Recombinant MtTOP1 proteins with single-cysteine substitutions were expressed via induction of the T7 promoter in E. coli ArcticExpress(DE3) RP strain (from Stratagene) and purified to homogeneity with the same procedures used for wild-type MtTOP1 . The relaxation activity assay was carried out with negatively supercoiled plasmid DNA substrate as described . The cleavage of supercoiled plasmid DNA by MtTOP1 was assayed according to published procedures .
CPM (7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin) labeling of MtTOP1-K524C protein
In preparation of the labeling reaction, a 32 μM solution of MtTOP1-K524C in storage buffer (100 mM potassium phosphate pH 7.4, 0.2 mM EDTA, 50% glycerol) was dialyzed against labeling buffer (100 mM potassium phosphate, pH 7.4, 50 mM KCl, 10% glycerol) overnight at 4°C. After dialysis, the protein concentration was determined to be 16 μM. The protein solution was incubated with 100 fold excess of TCEP (tris(2-carboxyethyl)phosphine) at room temperature for 10 min to keep the cysteine residue in the reduced state. Labeling was carried out by addition of 20 fold excess of CPM (Molecular Probes). Before and after each addition, the tube was flushed with 95% nitrogen gas. After CPM addition, the labeling reaction was allowed to proceed on ice for 6 hours. Removal of free dye was achieved by dialysis against labeling buffer. The labeled protein was analyzed by SDS-polyacrylamide gel electrophoresis and visualized by fluorescence from the incorporated CPM with the Storm 860 PhosphorImager and subsequently staining with MicrowaveBlue (from Protiga).
FRET experiments were performed in SCAN using the Varian Cary Eclipse fluorescence spectrophotometer. Excitation wavelength was set at 394 nm and emission was measured between 400-600 nm. The excitation and emission slits were set at 5 and 10 nm respectively. All FRET experiments were performed in labeling buffer with 1 mM MgCl2 at room temperature. CPM labeled MtTOP1-K524C (750 nM) was titrated with 50 and 100 nM solutions of oligonucleotide substrate (5'-GCTGCAATGTGATTTGGGATAATTAAGAGAGCAGC-3') modified with fluorescein at the 5' or 3' end (supplied by Sigma Genosys), or fluorescein attached via a 6 carbon linker to position 5 of the thymine base at the 20th nucleotide (custom synthesized by Integrated DNA Technologies). Control readings for the donor spectrum were performed by titrating MtTOP1-CPM K524C with buffer. Control readings for the acceptor spectrum were performed at excitation wavelength 495 nm by titrating MtTOP1-CPM K524C with 50 and 100 nM of fluorescein labeled oligos.
FRET efficiency calculations
where d+ = fraction of donor labeled molecules.
We thank Jingjing Wang for technical assistance. This research was supported by a grant from the National Institutes of Health (R01-GM054226) to YT.
- Schoeffler AJ, Berger JM: DNA topoisomerases: Harnessing and constraining energy to govern chromosome topology. Q Rev Biophys. 2008, 41: 41-101.PubMedView ArticleGoogle Scholar
- Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009, 9: 338-350. 10.1038/nrc2607.PubMedPubMed CentralView ArticleGoogle Scholar
- Hooper DC: Quinolone mode of action. Drugs. 1995, 49 (Suppl 2): 10-15. 10.2165/00003495-199500492-00004.PubMedView ArticleGoogle Scholar
- Drlica K, Malik M: Fluoroquinolones: Action and resistance. Curr Top Med Chem. 2003, 3: 249-282. 10.2174/1568026033452537.PubMedView ArticleGoogle Scholar
- Pommier Y: DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition. Chem Rev. 2009, 109: 2894-2902. 10.1021/cr900097c.PubMedPubMed CentralView ArticleGoogle Scholar
- Cheng B, Shukla S, Vasunilashorn S, Mukhopadhyay S, Tse-Dinh YC: Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J Biol Chem. 2005, 280: 38489-38495. 10.1074/jbc.M509722200.PubMedPubMed CentralView ArticleGoogle Scholar
- Cheng B, Annamalai T, Sorokin E, Abrenica M, Aedo S, Tse-Dinh YC: Asp-to-asn substitution at the first position of the DxD TOPRIM motif of recombinant bacterial topoisomerase I is extremely lethal to E. coli. J Mol Biol. 2009, 385: 558-567. 10.1016/j.jmb.2008.10.073.PubMedPubMed CentralView ArticleGoogle Scholar
- Tse-Dinh YC: Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res. 2009, 37: 731-737. 10.1093/nar/gkn936.PubMedPubMed CentralView ArticleGoogle Scholar
- Wang JC: Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 2002, 3: 430-440. 10.1038/nrm831.PubMedView ArticleGoogle Scholar
- Sassetti CM, Boyd DH, Rubin EJ: Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol. 2003, 48: 77-84. 10.1046/j.1365-2958.2003.03425.x.PubMedView ArticleGoogle Scholar
- Sassetti CM, Rubin EJ: Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA. 2003, 100: 12989-12994. 10.1073/pnas.2134250100.PubMedPubMed CentralView ArticleGoogle Scholar
- Nagaraja V, Sikder D, Jain P: DNA topoisomerase I from mycobacteria--a potential drug target. Curr Pharm Des. 2002, 8: 1995-2007. 10.2174/1381612023393567.PubMedView ArticleGoogle Scholar
- Wang Y, Lynch AS, Chen SJ, Wang JC: On the molecular basis of the thermal sensitivity of an Escherichia coli topA mutant. J Biol Chem. 2002, 277: 1203-1209. 10.1074/jbc.M109436200.PubMedView ArticleGoogle Scholar
- Zumstein L, Wang JC: Probing the structural domains and function in vivo of Escherichia coli DNA topoisomerase I by mutagenesis. J Mol Biol. 1986, 191: 333-340. 10.1016/0022-2836(86)90130-0.PubMedView ArticleGoogle Scholar
- Zhu CX, Roche CJ, Papanicolaou N, DiPietrantonio A, Tse-Dinh YC: Site-directed mutagenesis of conserved aspartates, glutamates and arginines in the active site region of Escherichia coli DNA topoisomerase I. J Biol Chem. 1998, 273: 8783-8789. 10.1074/jbc.273.15.8783.PubMedView ArticleGoogle Scholar
- Aravind L, Leipe DD, Koonin EV: Toprim--a conserved catalytic domain in type IA and II topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res. 1998, 26: 4205-4213. 10.1093/nar/26.18.4205.PubMedPubMed CentralView ArticleGoogle Scholar
- Annamalai T, Dani N, Cheng B, Tse-Dinh YC: Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol. BMC Biochem. 2009, 10: 18-10.1186/1471-2091-10-18.PubMedPubMed CentralView ArticleGoogle Scholar
- Kirkegaard K, Pflugfelder G, Wang JC: The cleavage of DNA by type-I DNA topoisomerases. Cold Spring Harb Symp Quant Biol. 1984, 49: 411-419.PubMedView ArticleGoogle Scholar
- Tse YC, Kirkegaard K, Pflugfelder G, Wang JC: Covalent bonds between protein and DNA. formation of phosphotyrosine linkage between certain DNA topoisomerases and DNA. J Biol Chem. 1980, 255: 5560-5565.PubMedGoogle Scholar
- Tse-Dinh YC: Zinc (II) coordination in Escherichia coli DNA topoisomerase I is required for cleavable complex formation with DNA. J Biol Chem. 1991, 266: 14317-14320.PubMedGoogle Scholar
- Bhaduri T, Bagui TK, Sikder D, Nagaraja V: DNA topoisomerase I from Mycobacterium smegmatis. An enzyme with distinct features. J Biol Chem. 1998, 273: 13925-13932. 10.1074/jbc.273.22.13925.PubMedView ArticleGoogle Scholar
- Zhu CX, Tse-Dinh YC: The acidic triad conserved in type IA DNA topoisomerases is required for binding of Mg(II) and subsequent conformational change. J Biol Chem. 2000, 275: 5318-5322. 10.1074/jbc.275.8.5318.PubMedView ArticleGoogle Scholar
- Bhat AG, Leelaram MN, Hegde SM, Nagaraja V: Deciphering the distinct role for the metal coordination motif in the catalytic activity of Mycobacterium smegmatis topoisomerase I. J Mol Biol. 2009, 393: 788-802. 10.1016/j.jmb.2009.08.064.PubMedView ArticleGoogle Scholar
- Tse-Dinh YC: Bacterial and archeal type I topoisomerases. Biochim Biophys Acta. 1998, 1400: 19-27.PubMedView ArticleGoogle Scholar
- Viard T, de la Tour CB: Type IA topoisomerases: A simple puzzle?. Biochimie. 2007, 89: 456-467. 10.1016/j.biochi.2006.10.013.PubMedView ArticleGoogle Scholar
- Caron PR: Compendium of DNA topoisomerase sequences. Methods Mol Biol. 1999, 94: 279-316.PubMedGoogle Scholar
- Pieper U, Eswar N, Webb BM, Eramian D, Kelly L, Barkan DT, Carter H, Mankoo P, Karchin R, Marti-Renom MA: MODBASE, a database of annotated comparative protein structure models and associated resources. Nucleic Acids Res. 2009, 37: D347-354. 10.1093/nar/gkn791.PubMedPubMed CentralView ArticleGoogle Scholar
- Liu IF, Annamalai T, Sutherland JH, Tse-Dinh YC: Hydroxyl radicals are involved in cell killing by the bacterial topoisomerase I cleavage complex. J Bacteriol. 2009, 191: 5315-5319. 10.1128/JB.00559-09.PubMedPubMed CentralView ArticleGoogle Scholar
- Perry K, Mondragón A: Structure of a complex between E. coli DNA topoisomerase I and single-stranded DNA. Structure. 2003, 11: 1349-1358. 10.1016/j.str.2003.09.013.PubMedView ArticleGoogle Scholar
- Maddry JA, Ananthan S, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Reynolds RC, Secrist JA, Sosa MI: Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb). 2009, 89: 354-363. 10.1016/j.tube.2009.07.006.View ArticleGoogle Scholar
- Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC: High-throughput screening for inhibitors of mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb). 2009, 89: 334-353. 10.1016/j.tube.2009.05.008.View ArticleGoogle Scholar
- Bjornsti MA, Wang JC: Expression of yeast DNA topoisomerase I can complement a conditional-lethal DNA topoisomerase I mutation in Escherichia coli. Proc Natl Acad Sci USA. 1987, 84: 8971-8975. 10.1073/pnas.84.24.8971.PubMedPubMed CentralView ArticleGoogle Scholar
- Sharff A, Fanutti C, Shi J, Calladine C, Luisi B: The role of the TolC family in protein transport and multidrug efflux. from stereochemical certainty to mechanistic hypothesis. Eur J Biochem. 2001, 268: 5011-5026. 10.1046/j.0014-2956.2001.02442.x.PubMedView ArticleGoogle Scholar
- Sampson BA, Benson SA: Identification and characterization of a new gene of escherichia coli K-12 involved in outer membrane permeability. Genetics. 1989, 122: 491-501.PubMedPubMed CentralGoogle Scholar
- Pruss GJ, Franco RJ, Chevalier SG, Manes SH, Drlica K: Effects of DNA gyrase inhibitors in Escherichia coli topoisomerase I mutants. J Bacteriol. 1986, 168: 276-282.PubMedPubMed CentralGoogle Scholar
- Zhu CX, Tse-Dinh YC: Overexpression and purification of bacterial DNA topoisomerase I. Methods Mol Biol. 1999, 94: 145-151.PubMedGoogle Scholar
- Lorenz M, Diekmann S: Distance determination in protein-DNA complexes using fluorescence resonance energy transfer. Methods Mol Biol. 2006, 335: 243-255.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.